XENE โ Xenon Pharmaceuticals ยท catalysts, narrative & risks
Xenon Pharmaceuticals (XENE) โ Research Snapshot as of October 8, 2026
Below is a factual synthesis of catalysts, narratives, risks, and scheduled events drawn from the sources. It is not investment advice. Analyst price targets and market context are reported as data points that have shifted over time, not as forecasts.
Positioning and price context
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company, HQ'd in Burnaby, Canada, listed on NASDAQ [20]. As of the report date the stock trades near $36.16, down roughly 40% from its year-to-date high of $72.66, with a market capitalization of about $3.5 billion and ~96.84 million shares outstanding [15], [20]. (An independent calendar put the market cap at ~$3.64B as of October 6.) [2] It pays no dividend [19].
Key recent catalysts (last ~1โ3 months)
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ